Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 134

1.

Regulatory T cells inhibit CD8(+) T-cell tissue invasion in human skin graft-versus-host reactions.

Mavin E, Ahmed SS, O'Boyle G, Turner B, Douglass S, Norden J, Collin M, Ali S, Dickinson A, Wang XN.

Transplantation. 2012 Sep 15;94(5):456-64. doi: 10.1097/TP.0b013e31826205d6.

PMID:
22890131
2.

Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming.

Wang XN, Haniffa MA, Holtick U, Collin MP, Jackson G, Hilkens CM, Holler E, Edinger M, Hoffmann P, Dickinson AM.

Transplantation. 2009 Jul 27;88(2):188-97. doi: 10.1097/TP.0b013e3181ac14ce.

PMID:
19623013
3.

Therapeutic effect of CXCR3-expressing regulatory T cells on liver, lung and intestinal damages in a murine acute GVHD model.

Hasegawa H, Inoue A, Kohno M, Lei J, Miyazaki T, Yoshie O, Nose M, Yasukawa M.

Gene Ther. 2008 Feb;15(3):171-82.

PMID:
17989707
4.

CXCR3 <-> ligand-mediated skin inflammation in cutaneous lichenoid graft-versus-host disease.

Wenzel J, Lucas S, Zahn S, Mikus S, Metze D, Ständer S, von Stebut E, Hillen U, Bieber T, Tüting T.

J Am Acad Dermatol. 2008 Mar;58(3):437-42. doi: 10.1016/j.jaad.2007.10.647.

PMID:
18280341
5.

CXCR3-mediated skin homing of autoreactive CD8 T cells is a key determinant in murine graft-versus-host disease.

Villarroel VA, Okiyama N, Tsuji G, Linton JT, Katz SI.

J Invest Dermatol. 2014 Jun;134(6):1552-60. doi: 10.1038/jid.2014.2.

6.

Chemokine-mediated tissue recruitment of CXCR3+ CD4+ T cells plays a major role in the pathogenesis of chronic GVHD.

Croudace JE, Inman CF, Abbotts BE, Nagra S, Nunnick J, Mahendra P, Craddock C, Malladi R, Moss PA.

Blood. 2012 Nov 15;120(20):4246-55. doi: 10.1182/blood-2012-02-413260.

7.

IFN-γ production by allogeneic Foxp3+ regulatory T cells is essential for preventing experimental graft-versus-host disease.

Koenecke C, Lee CW, Thamm K, Föhse L, Schafferus M, Mittrücker HW, Floess S, Huehn J, Ganser A, Förster R, Prinz I.

J Immunol. 2012 Sep 15;189(6):2890-6. doi: 10.4049/jimmunol.1200413.

8.

[Expressions of CXCL9, CXCL10 and CXCL11 in renal tubular epithelial cells induced by IFN-γ].

Lin Q, Song Y, Zhu X, Yang S, Zheng J.

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2013 Feb;29(2):137-40. Chinese.

PMID:
23388331
9.

Inhibition of graft-versus-host disease by double-negative regulatory T cells.

Young KJ, DuTemple B, Phillips MJ, Zhang L.

J Immunol. 2003 Jul 1;171(1):134-41.

10.

Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: An amplification cycle triggering cutaneous lupus erythematosus.

Meller S, Winterberg F, Gilliet M, Müller A, Lauceviciute I, Rieker J, Neumann NJ, Kubitza R, Gombert M, Bünemann E, Wiesner U, Franken-Kunkel P, Kanzler H, Dieu-Nosjean MC, Amara A, Ruzicka T, Lehmann P, Zlotnik A, Homey B.

Arthritis Rheum. 2005 May;52(5):1504-16.

11.

Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma.

Dengel LT, Norrod AG, Gregory BL, Clancy-Thompson E, Burdick MD, Strieter RM, Slingluff CL Jr, Mullins DW.

J Immunother. 2010 Nov-Dec;33(9):965-74. doi: 10.1097/CJI.0b013e3181fb045d.

12.

Natural killer T cells regulate the homing of chemokine CXC receptor 3-positive regulatory T cells to the liver in mice.

Santodomingo-Garzon T, Han J, Le T, Yang Y, Swain MG.

Hepatology. 2009 Apr;49(4):1267-76. doi: 10.1002/hep.22761.

PMID:
19140218
13.

CXCR3 internalization following T cell-endothelial cell contact: preferential role of IFN-inducible T cell alpha chemoattractant (CXCL11).

Sauty A, Colvin RA, Wagner L, Rochat S, Spertini F, Luster AD.

J Immunol. 2001 Dec 15;167(12):7084-93.

14.

Intervention of MAdCAM-1 or fractalkine alleviates graft-versus-host reaction associated intestinal injury while preserving graft-versus-tumor effects.

Ueha S, Murai M, Yoneyama H, Kitabatake M, Imai T, Shimaoka T, Yonehara S, Ishikawa S, Matsushima K.

J Leukoc Biol. 2007 Jan;81(1):176-85.

PMID:
17053165
15.

The CXCR3 targeting chemokine CXCL11 has potent antitumor activity in vivo involving attraction of CD8+ T lymphocytes but not inhibition of angiogenesis.

Hensbergen PJ, Wijnands PG, Schreurs MW, Scheper RJ, Willemze R, Tensen CP.

J Immunother. 2005 Jul-Aug;28(4):343-51.

PMID:
16000952
16.

Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding.

Cox JH, Dean RA, Roberts CR, Overall CM.

J Biol Chem. 2008 Jul 11;283(28):19389-99. doi: 10.1074/jbc.M800266200.

17.

Chemokine monokine induced by IFN-gamma/CXC chemokine ligand 9 stimulates T lymphocyte proliferation and effector cytokine production.

Whiting D, Hsieh G, Yun JJ, Banerji A, Yao W, Fishbein MC, Belperio J, Strieter RM, Bonavida B, Ardehali A.

J Immunol. 2004 Jun 15;172(12):7417-24.

18.

A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.

He S, Cao Q, Qiu Y, Mi J, Zhang JZ, Jin M, Ge H, Emerson SG, Zhang Y, Zhang Y.

J Immunol. 2008 Dec 1;181(11):7581-92.

19.
20.

Expression of chemokines in GVHD target organs is influenced by conditioning and genetic factors and amplified by GVHR.

Mapara MY, Leng C, Kim YM, Bronson R, Lokshin A, Luster A, Sykes M.

Biol Blood Marrow Transplant. 2006 Jun;12(6):623-34.

Supplemental Content

Support Center